FDA Clearance of IND Application for TACC3 PPI Inhibitor A2A-252 in Women's Cancer
- A2A Pharma
- May 22, 2023
- 0 min read
top of page
Search
Recent Posts
See AllMay 27, 2025 - A2A Pharmaceuticals a clinical stage oncology company with the lead asset AO-252, a PPI inhibitor of TACC3 which is a 1st...
Biomea Fusion, Inc., a precision oncology company dedicated to developing innovative medicines targeting genomically defined alterations...
A2A Pharmaceuticals Inc. Today Announced a Multi-target Co-development Agreement With Daewoong Pharmaceutical for AI-enhanced Oncology...
bottom of page